Medivation has 'best-in-class' ambitions for newly purchased PARP inhibitor

Medivation ($MDVN) made a name for itself with Xtandi, the prostate cancer med that's now giving Johnson & Johnson's ($JNJ) Zytiga a run for its money. Now, it wants to challenge other drugmakers in the PARP inhibitor field, too. And as analysts point out, Medivation thinks the PARP med it picked up from BioMarin ($BMRN) this week could be a "best-in-class" performer. Report